Radius Health drug cuts fracture risk

Waltham, MA-based Radius Health’s investigational drug abaloparatide-SC (subcutaneous) increases bone mineral density in the spine and hip in postmenopausal women with osteoporosis and may reduce their risk of vertebral and nonvertebral fractures, according to research presented April 1 at Endo 2016, the annual meeting of the Endocrine Society, in Boston. Researchers investigated patients enrolled in the randomized, double-blind, comparative, multicenter international phase 3 ACTIVE clinical trial to evaluate the efficacy and safety of 80 µg of abaloparatide-SC for preventing fractures in otherwise healthy ambulatory postmeno­pausal women with osteoporosis. Overall, 2463 patients aged between 49 and 86 years were randomized to one of three treatment arms for 18 months: double-blind 80 µg of abaloparatide-SC, blind-matched placebo, or open-label 20 µg of subcutaneous teriparatide

Waltham, MA-based Radius Health’s investigational drug abaloparatide-SC (subcutaneous) increases bone mineral density in the spine and hip in postmenopausal women with osteoporosis and may reduce their risk of vertebral and nonvertebral fractures, according to research presented April 1 at Endo 2016, the annual meeting of the Endocrine Society, in Boston. Researchers investigated patients enrolled in the randomized, double-blind, comparative, multicenter international phase 3 ACTIVE clinical trial to evaluate the efficacy and safety of 80 µg of abaloparatide-SC for preventing fractures in otherwise healthy ambulatory postmeno­pausal women with osteoporosis. Overall, 2463 patients aged between 49 and 86 years were randomized to one of three treatment arms for 18 months: double-blind 80 µg of abaloparatide-SC, blind-matched placebo, or open-label 20 µg of subcutaneous teriparatide

Continue reading here:
Radius Health drug cuts fracture risk

Related posts:

  1. Are Metatarsal Fractures Indicative of Osteoporosis in Postmenopausal Women?
  2. Down syndrome associated with increased radius and tibia fragility
  3. Thromboprophylaxis in Ambulatory Trauma Patients With Foot and Ankle Fractures: Prospective Study Using a Risk Scoring System
  4. Effect of curettage after segmental phenolization in the treatment of onychocryptosis: A randomized double-blind clinical trial
  5. Effect of WF10 (Immunokine) on Diabetic Foot Ulcer Therapy: A Double-blind, Randomized, Placebo-controlled Trial – Corrected Proof
  6. Effect of WF10 (Immunokine) on Diabetic Foot Ulcer Therapy: A Double-blind, Randomized, Placebo-controlled Trial
  7. Muscle drug gets breakthrough status
  8. A randomized controlled trial of custom foot orthoses for the treatment of plantar heel pain
  9. Study questions effectiveness of adjunctive HBOT for DFUs
  10. At-Risk Patients Gain Attention of Health Insurers – NYTimes.com